Featured articles from the journal CHEST®, November 2022

The November issueopens in new tab/window of CHEST contains 51 articles, including clinically relevant research, reviews, case series, commentary and more. Each month, the journal also offers complementary web and multimedia activitiesopens in new tab/window, including visual abstracts, to expand the reach of its most interesting, timely and relevant research.

“Included in the November issue of the journal CHEST is the latest guideline on Perioperative Management of Antithrombotic Therapyopens in new tab/window,” says Editor-in-Chief, Peter Mazzone, MD, MPH, FCCP. “An update to the 2012 edition, the new guideline addresses 43 Patients-Interventions-Comparators-Outcomes questions related to the perioperative management of patients who are receiving long-term oral anticoagulant or antiplatelet therapy and require an elective surgery or procedure.”

Also included in the current issue of CHEST:

• Chest Infections

  In original research, “Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19opens in new tab/window,” results did not support the use of convalescent plasma as a treatment for adults hospitalized with COVID-19. A visual abstract for the research can be viewed hereopens in new tab/window and an animation of the research can be viewed hereopens in new tab/window.

• COPD

“Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapyopens in new tab/window” finds that single-inhaler triple therapy was associated with significant reductions in health care resource use, with consequent cost savings. A visual abstract for the research can be viewed hereopens in new tab/window.

• Education and Clinical Practice

Associated with Long COVID, “Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndromeopens in new tab/window” finds that pyridostigmine improves aerobic capacity in ME/CFS.

• Sleep

Looking at short-term changes, “Air Pollution and the Effectiveness of Positive Airway Pressure Therapy in Individuals with Sleep Apneaopens in new tab/window” demonstrated that air pollution, even at the relatively low levels, showed a measurable association with a change in objective PAP treatment effectiveness. A visual abstract for the research can be viewed hereopens in new tab/window.

---

Notes for editors

To view the entire November issue of CHEST journal (volume 162, issue 5), published by Elsevier, visit journal.chestnet.orgopens in new tab/window and follow @journal_CHESTopens in new tab/window on Twitter for the latest journal news.

Full text of these articles and interviews with the authors are available to credentialed journalists upon request; contact Laura DiMasi, PR and Communications Specialist, American College of Chest Physicians (CHEST), at [email protected]opens in new tab/window.

About the journal CHEST^®

The journal CHESTopens in new tab/window, the official publication of the American College of Chest Physicians®, features the best in peer-reviewed, cutting-edge original research in the multidisciplinary specialties of chest medicine: pulmonary, critical care, and sleep medicine; thoracic surgery; cardiorespiratory interactions; and related disciplines. Published since 1935, it is home to the highly regarded clinical practice guidelines and consensus statements. Access the journal CHEST online at journal.chestnet.orgopens in new tab/window.

About the American College of Chest Physicians

The American College of Chest Physicians^® (CHEST) is the global leader in the prevention, diagnosis, and treatment of chest diseases. Its mission is to champion advanced clinical practice, education, communication, and research in chest medicine. It serves as an essential connection to clinical knowledge and resources for its 19,000+ members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For information about the American College of Chest Physicians, and its flagship journal CHEST^®, visit chestnet.org.opens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.